1. Home
  2. RYTM vs BMA Comparison

RYTM vs BMA Comparison

Compare RYTM & BMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • BMA
  • Stock Information
  • Founded
  • RYTM 2008
  • BMA 1966
  • Country
  • RYTM United States
  • BMA Argentina
  • Employees
  • RYTM N/A
  • BMA N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • BMA Commercial Banks
  • Sector
  • RYTM Health Care
  • BMA Finance
  • Exchange
  • RYTM Nasdaq
  • BMA Nasdaq
  • Market Cap
  • RYTM 4.3B
  • BMA 4.7B
  • IPO Year
  • RYTM 2017
  • BMA 2006
  • Fundamental
  • Price
  • RYTM $65.25
  • BMA $69.39
  • Analyst Decision
  • RYTM Strong Buy
  • BMA Hold
  • Analyst Count
  • RYTM 12
  • BMA 3
  • Target Price
  • RYTM $77.50
  • BMA $54.50
  • AVG Volume (30 Days)
  • RYTM 585.3K
  • BMA 333.5K
  • Earning Date
  • RYTM 08-05-2025
  • BMA 08-21-2025
  • Dividend Yield
  • RYTM N/A
  • BMA 5.12%
  • EPS Growth
  • RYTM N/A
  • BMA N/A
  • EPS
  • RYTM N/A
  • BMA N/A
  • Revenue
  • RYTM $136,863,000.00
  • BMA $2,661,558,665.00
  • Revenue This Year
  • RYTM $37.56
  • BMA N/A
  • Revenue Next Year
  • RYTM $74.99
  • BMA $14.62
  • P/E Ratio
  • RYTM N/A
  • BMA N/A
  • Revenue Growth
  • RYTM 48.88
  • BMA N/A
  • 52 Week Low
  • RYTM $40.46
  • BMA $42.23
  • 52 Week High
  • RYTM $69.89
  • BMA $118.42
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 53.08
  • BMA 33.38
  • Support Level
  • RYTM $60.80
  • BMA $67.39
  • Resistance Level
  • RYTM $64.00
  • BMA $72.75
  • Average True Range (ATR)
  • RYTM 1.96
  • BMA 2.95
  • MACD
  • RYTM -0.13
  • BMA -0.01
  • Stochastic Oscillator
  • RYTM 44.48
  • BMA 17.29

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About BMA Banco Macro S.A. ADR (representing Ten Class B)

Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.

Share on Social Networks: